Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report

BACKGROUND: The evidence on the use of the oral dimethyl-fumarate after the discontinuation of treatment with natalizumab in people with Multiple Sclerosis is still little. Natalizumab discontinuation may induce the recurrence or rebound of the clinical and neuroradiological disease activity. Curren...

Descripción completa

Detalles Bibliográficos
Autores principales: Patti, Francesco, Leone, Carmela, Zappia, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672501/
https://www.ncbi.nlm.nih.gov/pubmed/26643473
http://dx.doi.org/10.1186/s12883-015-0512-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672501/
https://www.ncbi.nlm.nih.gov/pubmed/26643473
http://dx.doi.org/10.1186/s12883-015-0512-0

Ejemplares similares